Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.

[1]  R. Fernandes,et al.  Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[2]  R. Yasumatsu,et al.  Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study , 2020, International Journal of Clinical Oncology.

[3]  Hideaki Takahashi,et al.  Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients , 2020, Cancers.

[4]  N. Lee,et al.  Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Uchi,et al.  Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events , 2020, Acta oto-laryngologica.

[6]  R. Uchi,et al.  Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma , 2020, Cancers.

[7]  R. Ferris,et al.  Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) , 2020, Head & neck.

[8]  Hideaki Takahashi,et al.  Age‐based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study , 2020, Asia-Pacific journal of clinical oncology.

[9]  T. Gauler,et al.  HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. , 2020 .

[10]  S. Natsugoe,et al.  Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer , 2020, Oncology.

[11]  A. Horii,et al.  Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score , 2020, European Archives of Oto-Rhino-Laryngology.

[12]  R. Uchi,et al.  Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. , 2020, Auris, nasus, larynx.

[13]  R. Uchi,et al.  Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. , 2019, Oral oncology.

[14]  F. Bidault,et al.  Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.

[15]  K. Omori,et al.  Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma , 2019, Cancers.

[16]  Feiran Wang,et al.  Correlation between patients’ age and cancer immunotherapy efficacy , 2019, Oncoimmunology.

[17]  Jinming Yu,et al.  Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[18]  K. Harrington,et al.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. , 2018, Oral oncology.

[19]  X. Mielgo-Rubio,et al.  Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients , 2018, Clinical and Translational Oncology.

[20]  O. Merimsky,et al.  Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. , 2017, Lung cancer.

[21]  J. Ahn,et al.  Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  M. Monga,et al.  A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. , 2017, Oral oncology.

[23]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[24]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[25]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[26]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.